BASF and Colorcon Cooperate on Kollicoat IR for Ready-to-Use Pharmaceutical Coating Solutions
Colorcon and BASF have announced their co-operation for using immediate release coating polymer Kollicoat IR for Colorcon’s fully formulated ready-to-use coatings.
Colorcon will expand their PVA-based product portfolio by offering customers an alternative efficient and convenient solution for the immediate release coating of pharmaceuticals and dietary supplements. “With this new ready-to-use coating option formulators can benefit from both the coating performance of Kollicoat IR and Colorcon’s worldwide unique, customised services”, said Daniele Piergentili, Vice President Global Marketing Pharma Ingredients at BASF.
“Kollicoat IR provides Colorcon with the capability to further expand our film coating portfolio, bringing more choice to our customers while providing customized solutions. We are pleased to cooperate with BASF to bring Kollicoat IR to a wider market, combining BASF’s polymer expertise with Colorcon’s knowledge of formulated film coating systems and our global reach,” said Cornelis van den Muyzenberg, VP of Sales and Business Development at Colorcon.
Adding Kollicoat IR as an alternative for use in targeted Opadry complete film coating systems expands the cooperation between Colorcon and BASF.
Kollicoat IR, an ethylene glycol and vinyl alcohol graft copolymer, is BASF’s highly versatile and safe-in-use instant release coating polymer. This polymer enables processing at low temperatures and high solids content while delivering appropriate coating results.
Kollicoat is monographed in all major markets, and has furthermore received GRAS status (Generally Regarded As Safe) in the US and the European E-Number (E1209) for application in dietary/nutritional supplements.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance